Cargando…
Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients
Background: Bisdemethoxycurcumin (BDC) might be an inflammation inhibitor in Alzheimer’s Disease (AD). However, BDC is almost insoluble in water, poorly absorbed by the organism, and degrades rapidly. We thus developed a new nanoformulation of BDC based on H-Ferritin nanocages (BDC-HFn). Methods: We...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409287/ https://www.ncbi.nlm.nih.gov/pubmed/36012501 http://dx.doi.org/10.3390/ijms23169237 |
_version_ | 1784774814717706240 |
---|---|
author | Gagliardi, Stella Truffi, Marta Tinelli, Veronica Garofalo, Maria Pandini, Cecilia Cotta Ramusino, Matteo Perini, Giulia Costa, Alfredo Negri, Sara Mazzucchelli, Serena Bonizzi, Arianna Sitia, Leopoldo Busacca, Maria Sevieri, Marta Mocchi, Michela Ricciardi, Alessandra Prosperi, Davide Corsi, Fabio Cereda, Cristina Morasso, Carlo |
author_facet | Gagliardi, Stella Truffi, Marta Tinelli, Veronica Garofalo, Maria Pandini, Cecilia Cotta Ramusino, Matteo Perini, Giulia Costa, Alfredo Negri, Sara Mazzucchelli, Serena Bonizzi, Arianna Sitia, Leopoldo Busacca, Maria Sevieri, Marta Mocchi, Michela Ricciardi, Alessandra Prosperi, Davide Corsi, Fabio Cereda, Cristina Morasso, Carlo |
author_sort | Gagliardi, Stella |
collection | PubMed |
description | Background: Bisdemethoxycurcumin (BDC) might be an inflammation inhibitor in Alzheimer’s Disease (AD). However, BDC is almost insoluble in water, poorly absorbed by the organism, and degrades rapidly. We thus developed a new nanoformulation of BDC based on H-Ferritin nanocages (BDC-HFn). Methods: We tested the BDC-HFn solubility, stability, and ability to cross a blood–brain barrier (BBB) model. We tested the effect of BDC-HFn on AD and control (CTR) PBMCs to evaluate the transcriptomic profile by RNA-seq. Results: We developed a nanoformulation with a diameter of 12 nm to improve the solubility and stability. The comparison of the transcriptomics analyses between AD patients before and after BDC-HFn treatment showed a major number of DEG (2517). The pathway analysis showed that chemokines and macrophages activation differed between AD patients and controls after BDC-HFn treatment. BDC-HFn binds endothelial cells from the cerebral cortex and crosses through a BBB in vitro model. Conclusions: Our data showed how BDC-Hfn could improve the stability of BDC. Significant differences in genes associated with inflammation between the same patients before and after BDC-Hfn treatment have been found. Inflammatory genes that are upregulated between AD and CTR after BDC-HFn treatment are converted and downregulated, suggesting a possible therapeutic approach. |
format | Online Article Text |
id | pubmed-9409287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94092872022-08-26 Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients Gagliardi, Stella Truffi, Marta Tinelli, Veronica Garofalo, Maria Pandini, Cecilia Cotta Ramusino, Matteo Perini, Giulia Costa, Alfredo Negri, Sara Mazzucchelli, Serena Bonizzi, Arianna Sitia, Leopoldo Busacca, Maria Sevieri, Marta Mocchi, Michela Ricciardi, Alessandra Prosperi, Davide Corsi, Fabio Cereda, Cristina Morasso, Carlo Int J Mol Sci Article Background: Bisdemethoxycurcumin (BDC) might be an inflammation inhibitor in Alzheimer’s Disease (AD). However, BDC is almost insoluble in water, poorly absorbed by the organism, and degrades rapidly. We thus developed a new nanoformulation of BDC based on H-Ferritin nanocages (BDC-HFn). Methods: We tested the BDC-HFn solubility, stability, and ability to cross a blood–brain barrier (BBB) model. We tested the effect of BDC-HFn on AD and control (CTR) PBMCs to evaluate the transcriptomic profile by RNA-seq. Results: We developed a nanoformulation with a diameter of 12 nm to improve the solubility and stability. The comparison of the transcriptomics analyses between AD patients before and after BDC-HFn treatment showed a major number of DEG (2517). The pathway analysis showed that chemokines and macrophages activation differed between AD patients and controls after BDC-HFn treatment. BDC-HFn binds endothelial cells from the cerebral cortex and crosses through a BBB in vitro model. Conclusions: Our data showed how BDC-Hfn could improve the stability of BDC. Significant differences in genes associated with inflammation between the same patients before and after BDC-Hfn treatment have been found. Inflammatory genes that are upregulated between AD and CTR after BDC-HFn treatment are converted and downregulated, suggesting a possible therapeutic approach. MDPI 2022-08-17 /pmc/articles/PMC9409287/ /pubmed/36012501 http://dx.doi.org/10.3390/ijms23169237 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gagliardi, Stella Truffi, Marta Tinelli, Veronica Garofalo, Maria Pandini, Cecilia Cotta Ramusino, Matteo Perini, Giulia Costa, Alfredo Negri, Sara Mazzucchelli, Serena Bonizzi, Arianna Sitia, Leopoldo Busacca, Maria Sevieri, Marta Mocchi, Michela Ricciardi, Alessandra Prosperi, Davide Corsi, Fabio Cereda, Cristina Morasso, Carlo Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients |
title | Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients |
title_full | Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients |
title_fullStr | Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients |
title_full_unstemmed | Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients |
title_short | Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients |
title_sort | bisdemethoxycurcumin (bdc)-loaded h-ferritin-nanocages mediate the regulation of inflammation in alzheimer’s disease patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409287/ https://www.ncbi.nlm.nih.gov/pubmed/36012501 http://dx.doi.org/10.3390/ijms23169237 |
work_keys_str_mv | AT gagliardistella bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT truffimarta bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT tinelliveronica bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT garofalomaria bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT pandinicecilia bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT cottaramusinomatteo bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT perinigiulia bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT costaalfredo bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT negrisara bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT mazzucchelliserena bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT bonizziarianna bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT sitialeopoldo bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT busaccamaria bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT sevierimarta bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT mocchimichela bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT ricciardialessandra bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT prosperidavide bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT corsifabio bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT ceredacristina bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients AT morassocarlo bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients |